Home > Boards > US Listed > Biotechs > Cellectar Biosciences Inc. (CLRB)

Some highlight from the paragraph about CLR-131.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Sluicebox Member Profile
 
Followed By 2
Posts 185
Boards Moderated 0
Alias Born 08/12/19
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 1/12/2021 4:47:24 PM
Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) Edgar (US Regulatory) - 1/8/2021 4:32:39 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/28/2020 4:32:09 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/28/2020 4:32:04 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/28/2020 4:31:37 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/28/2020 4:16:55 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 12/23/2020 4:04:04 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/23/2020 10:35:16 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 12/23/2020 6:00:59 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/9/2020 4:05:25 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/9/2020 9:01:42 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/6/2020 4:07:48 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/10/2020 4:11:31 PM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 8/21/2020 6:02:58 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/17/2020 4:03:47 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/11/2020 4:27:10 PM
Securities Registration Statement (simplified Form) (s-3) Edgar (US Regulatory) - 8/11/2020 4:16:43 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/10/2020 8:31:37 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/10/2020 8:15:46 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/4/2020 4:06:41 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/21/2020 4:03:14 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 7/13/2020 2:38:51 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 7/10/2020 4:16:20 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 7/6/2020 6:32:07 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/6/2020 6:30:18 AM
Sluicebox   Tuesday, 07/28/20 09:44:07 AM
Re: None
Post # of 8038 
Some highlight from the paragraph about CLR-131.
CLR-131 exploit the altered lipid composition of cancer cell membranes to more actively target tumors and deliver the radioactive payload into the cancer cell.
Advantages of this system include the PDCs’ ability to gain entry into a wide variety of cancer types and indiscriminately target all cells within a tumor without relying on expression of a specific antigen.
Furthermore, this technology could offer considerable flexibility in the types of payloads that can be used.
Cellectar has several other PDCs in preclinical development.
CLR 131 could be the first of many such drugs from Cellectar, with other payloads being explored.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences